Scilight Press

Author Information

Received: 06 May 2024 | Revised: 19 Jun 2024 | Accepted: 21 Jun 2024 | Published: 20 Aug 2024

Abstract

Keywords

Cell Proliferation | cytotoxicity | assays | drug discovery

References 

• 1.
  Tennant, J.R. Evaluation of the trypan blue technique for determination of cell viability. Transplantation 1964, 2, 685–694.
• 2.
  Strober, W. Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. 2001, 21, A-3B.
• 3.
  Hussein, R.A.; Mohsin A.J. Trypan blue exclusion assay verifies in vitro cytotoxicity of new cis-platinum (II) complex in human cells. Baghdad Sci. J. 2019, 16, 555–559.
• 4.
  Rose, R.J.; Possingham J.V. The localization of (3H) thymidine incorporation in the DNA of replicating spinach chloroplasts by electron-microscope autoradiography. J. Cell Sci. 1976, 20, 341–355.
• 5.
  Crane, A.M.; Bhattacharya S.K. The use of bromodeoxyuridine incorporation assays to assess corneal stem cell proliferation. Methods Mol. Biol. 2013, 1014, 65–70.
• 6.
  Gratzner, H.G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982, 218, 474–475.
• 7.
  Bergler, W.; Petroianu, G.; Schadel A. Feasibility of proliferation studies using the BrdU and MTT assays with a head and neck carcinoma cell line. ORL 1993, 55, 230–235.
• 8.
  Lehmann, J.; Retz, M.; Sidhu, S.S.; et al. Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur. Urol. 2006, 50, 141–147.
• 9.
  Salic, A.; Mitchison T.J. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl. Acad. Sci. 2008, 105, 2415–2420.
• 10.
  McGowan, E.M.; Alling, N.; Jackson, E.A.; et al. Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: Pitfalls of the MTS assay. PLoS ONE 2011, 6, e20623.
• 11.
  Mead, T.J.; Lefebvre V. Proliferation assays (BrdU and EdU) on skeletal tissue sections. Methods Mol. Biol. 2014, 1130, 233–243.
• 12.
  Balu, D.T.; Hodes, G.E.; Hill, T.E.; et al. Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse. J. Pharmacol. Toxicol. Methods 2009, 59, 100–107.
• 13.
  Lee, Y.S.; Yi, J.S.; Seo, S.J.; et al. Comparison of BALB/c and CBA/J mice for the local lymph node assay using bromodeoxyuridine with flow cytometry (LLNA: BrdU-FCM). Regul. Toxicol. Pharm. 2017, 83, 13–22.
• 14.
  Zou, J.; Wu, K.; Lin, C.; et al. LINC00319 acts as a microRNA-335-5p sponge to accelerate tumor growth and metastasis in gastric cancer by upregulating ADCY3. Am. J. Physiol. Gastrointest. Liver Physiol. 2020, 318, G10–G22.
• 15.
  Staszkiewicz, J.; Gimble, J.; Cain, C.; et al. Flow cytometric and immunohistochemical detection of in vivo BrdU-labeled cells in mouse fat depots. Biochem. Biophys. Res. Commun. 2009, 378, 539–544.
• 16.
  Berridge, M.V.; Herst, P.M.; Tan A.S. Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction. Biotechnol. Annu. Rev. 2005, 11, 127–152.
• 17.
  Marks, D.C.; Belov, L.; Davey, M.W.; et al. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leukemia Res. 1992, 16, 1165–1173.
• 18.
  Gomez Perez, M.; Fourcade, L.; Mateescu, M.A.; et al. Neutral Red versus MTT assay of cell viability in the presence of copper compounds. Anal. Biochem. 2017, 535, 43–46.
• 19.
  Paull, K.D.; Shoemaker, R.H.; Boyd, M.R.; et al. The synthesis of XTT: A new tetrazolium reagent that is bioreducible to a water‐soluble formazan. Heterocycl. Chem. 1988, 25, 911–914.
• 20.
  Roehm, N.W.; Rodgers, G.H.; Hatfield, S.M.; et al. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 1991, 142, 257–265.
• 21.
  Schröterová L.; Králová V.; Voráčová A.; et al. Antiproliferative effects of selenium compounds in colon cancer cells: Comparison of different cytotoxicity assays. Toxicol. Vitro 2009, 23, 1406–1411.
• 22.
  Berridge, M.; Tan A. Trans-plasma membrane electron transport: A cellular assay for NADH-and NADPH-oxidase based on extracellular, superoxide-mediated reduction of the sulfonated tetrazolium salt WST-1. Protoplasma 1998, 205, 74–82.
• 23.
  Weidmann, E.; Brieger, J.; Jahn, B.; et al. Lactate dehydrogenase-release assay: A reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann. Hematol. 1995, 70, 153–158.
• 24.
  Kumar, P.; Nagarajan, A.; Uchil P.D. Analysis of Cell Viability by the Lactate Dehydrogenase Assay. Cold Spring Harb. Protoc. 2018, 2018, pdb-prot095497.
• 25.
  Drent, M.; Cobben, N.A.; Henderson, R.F.; et al. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur. Respir. J. 1996, 9, 1736–1742.
• 26.
  Decker, T.; Lohmann-Matthes M.-L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 1988, 115, 61–69.
• 27.
  Vives‐Bauza, C.; Yang, L.; Manfredi G. Assay of Mitochondrial ATP Synthesis in Animal Cells and Tissues. Methods Cell Biol. 2007, 80, 155–171.
• 28.
  Tanaka, H.; Shinji, T.; Sawada, K.; et al. Development and application of a bioluminescence ATP assay method for rapid detection of coliform bacteria. Water Res. 997, 31, 1913–1918.
• 29.
  Atkinson, D.E.; Atkinson D.E. Cellular Energy Metabolism and Its Regulations; Elsevier: Amsterdam, The Netherlands, 1977.
• 30.
  Deininger, R.A.; Lee J. Rapid determination of bacteria in drinking water using an ATP assay. Field Anal. Chem. Technol. 2001, 5, 185–189.
• 31.
  Long, J.A.; Guthrie H.D. Validation of a rapid, large-scale assay to quantify ATP concentration in spermatozoa. Theriogenology 2006, 65, 1620–1630.
• 32.
  Taylor, A.L.; Kudlow, B.A.; Marrs, K.L.; et al. Bioluminescence detection of ATP release mechanisms in epithelia. Am. J. Physiol.-Cell Physiol. 1998, 275, C1391–C1406.
• 33.
  Weston, S.A.; Parish C.R. New fluorescent dyes for lymphocyte migration studies: Analysis by flow cytometry and fluorescence microscopy. J. Immunol. Methods 1990, 133, 87–97.
• 34.
  Lašt’ovička, J.; Budinský V.; Špíšek, R.; et al. Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers. Cell. Immunol. 2009, 256, 79–85.
• 35.
  Wang, X.M.; Terasaki, P.I.; Rankin G.W., Jr.; et al. A new microcellular cytotoxicity test based on calcein AM release. Human Immunol. 1993, 37, 264–270.
• 36.
  Bratosin, D.; Mitrofan, L.; Palii, C.; et al. Novel fluorescence assay using calcein‐AM for the determination of human erythrocyte viability and aging. Cytom. Part A J. Int. Soc. Anal. Cytol. 2005, 66, 78–84.
• 37.
  Stefanowicz-Hajduk, J.; Ochocka J.R. Real-time cell analysis system in cytotoxicity applications: Usefulness and comparison with tetrazolium salt assays. Toxicol. Rep. 2020, 7, 335–344.
• 38.
  Keogh, R.J. New technology for investigating trophoblast function. Placenta 2010, 31, 347–350.
• 39.
  Ferrer, M.D.; Rodriguez, J.C.; Álvarez, L.; et al. Effect of antibiotics on biofilm inhibition and induction measured by real‐time cell analysis. J. Appl. Microbiol. 2017, 122, 640–650.
• 40.
  Franken, N.A.; Rodermond, H.M.; Stap, J.; et al. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1, 2315–2319.
• 41.
  Plumb, J.A. Cell sensitivity assays: Clonogenic assay. In Cancer Cell Culture: Methods and Protocols; Humana Press: Totowa, NJ, USA, 2004; pp. 159–164.
• 42.
  Ross, A.A.; Cooper, B.W.; Lazarus, H.M.; et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993, 82, 2605–2610.
• 43.
  Nicoletti, I.; Migliorati, G.; Pagliacci, M.C.; et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 1991, 139, 271–279.
• 44.
  Chazotte, B. Labeling nuclear DNA with hoechst 33342. Cold Spring Harbor Protoc. 2011, 2011, pdb-prot5557.
• 45.
  Barbosa, M.A.; Xavier, C.P.; Pereira, R.F.; et al. 3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs. Cancers 2021, 14, 190.
• 46.
  Mollaei, M.; Hassan, Z.M.; Khorshidi, F.; et al. Chemotherapeutic drugs: Cell death-and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl. Oncol. 2021, 14, 101056.
• 47.
  Recasens, A.; Munoz L. Targeting cancer cell dormancy. Trends Pharmacol. Sci. 2019, 40, 128–141.
• 48.
  Debnath, J.; Gammoh, N.; Ryan K.M. Autophagy and autophagy-related pathways in cancer. Nat. Rev. Mol. Cell Biol. 2023, 24, 560–575.
• 49.
  Wang, Y.; He Q.-Y.; Sun, R.W.Y.; et al. Gold (III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 2005, 65, 11553–11564.
• 50.
  Priestley, P.; Baber, J.; Lolkema, M.P.; et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 2019, 575, 210–216.
• 51.
  Salk, J.J.; Fox, E.J.; Loeb L.A. Mutational heterogeneity in human cancers: Origin and consequences. Annu. Rev. Pathol. Mech. Dis. 2010, 5, 51–75.
• 52.
  Hayes, T.K.; Aquilanti, E.; Persky, N.S.; et al. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nat. Commun. 2024, 15, 2742.
• 53.
  Yazlovitskaya, E.M.; DeHaan, R.D.; Persons D.L. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem. Biophys. Res. Commun. 2001, 283, 732–737.
• 54.
  Vanhoefer, U.; Müller, M.R.; Hilger, R.A.; et al. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br. J. Cancer 1999, 81, 1304–1310.
• 55.
  Jaaks, P.; Coker, E.A.; Vis, D.J.; et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 2022, 603, 166–173.
• 56.
  Tyner, J.W.; Haderk, F.; Kumaraswamy, A.; et al. Understanding drug sensitivity and tackling resistance in cancer. Cancer Res. 2022, 82, 1448–1460.
• 57.
  Workman, P. The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer Drugs. Cancer Res. 2023, 83, 3170–3173.
• 58.
  Gerdes, H.; Casado, P.; Dokal, A.; et al. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. Nat. Commun. 2021, 12, 1850.
• 59.
  Levatić J.; Salvadores, M.; Fuster-Tormo, F.; et al. Mutational signatures are markers of drug sensitivity of cancer cells. Nat. Commun. 2022, 13, 2926.